drugset / Trial / NCT01355081

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

NCT01355081

Phase 3 Completed 366 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder. The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Lu AA21004, once daily (QD), in Japanese participants with major depressive disorder.

Timeline

Start
2011-05
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral